Our Mission: Stronger Evidence

ObvioHealth is on a mission to conduct innovative and efficient trials that deliver stronger evidence for better health outcomes. We use technology to develop more precise and accessible measurement tools to capture more robust and accurate data—so life-improving innovations can get to market faster.

“I have been struck again and again by how important measurement is to improving the human condition."

Bill Gates

Our Difference: Tech and Team

Our success comes from the fusion of experienced clinical researchers and pioneering health technology.

ObvioGo™ DCT Platform and App

Powerful, flexible technology to capture and unify more accurate multi-source data.

Virtual Site (COACH) Team

Personalized human connection to boost compliance and retention.

DCT Consulting and CRO Services

Expertise to design and conduct studies from start to finish.

Digital Instruments and Endpoint Expertise

The right tools, outcomes, and endpoints to power studies and deliver stronger evidence.

ObvioHealth in Numbers

ObvioHealth has been innovating clinical trials since 2017, when we launched one of the first-ever DCT platforms with a mobile app. Today, we are an industry leader, designing and running DCTs across the globe that generate more robust and accurate data.

60+

Studies

28

Countries across 5 continents

20

Therapeutic Areas
Co-creating the future of clinical trials with these industry leaders.

Meet Our Leadership

Ivan Jarry

Chief Executive Officer

Matty Culbreth-Notaro

Chief Operations Officer

Craig Gravina

Chief Technology Officer

Ryan Shortreed

Chief Financial Officer

Scott Dixon

Chief Commercial Officer

Leslie Pascaud

Chief Marketing Officer

Cheryl Walter

Chief Talent Officer

James Hendrick

Sr. VP, Strategic Accounts and Real-World Evidence

Our Strategic Partners

Our Story: DCT is in Our DNA

We were purpose-built from the ground up to conduct decentralized clinical trials.

2017

Company Launch

2018

Development of patient-facing mobile app

2019

Completion of first virtual trial in APAC

2020

Launch of Obvio-19, a remote COVID-19 registry
Completion of first virtual trial in dermatology
Strategic alliance signed with IQVIA

2021

Completion of the world’s first fully virtual urogynecology study
Completion of first COVID-19 interventional study with device integration
RWE partnership agreement signed with Dedalus
Partnership signed with Novotech

2022

Launch of ObvioGo™, our next-generation, configurable DCT platform
Received approval from the FDA to launch a first-of-its-kind, virtual infant nutrition study
Collaboration agreement signed with Oracle
Launch of first fully virtual DTx study for migraines

Meet our Advisory Board

Susan Dallabrida, PhD

Chairwoman

Bill Taaffe

Member

Donna Reed

Member

Graham Bunn

Member

Nelly Conus

Member

Steve Heath

Member

Sunil Joshi

Member

Awards and Recognition

Everest PEAK Matrix®

Inc. 5000 (2x)

Reuters Finalist—Most Valuable Clinical Technology

Scrip Shortlist 

CB News Shortlist  

Our Current Trials

With a growing list of trials scheduled for launch in 2023, we are constantly innovating to find ways to further reduce patient burden while increasing data accuracy across a range of therapeutic areas.

Work for Us

Remote and hybrid positions, unlimited PTO, and company stock grants are just a few benefits of working for ObvioHealth.